Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity

Summary

The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab. The study aims to describe the efficacy for dapagliflozin as compared to standard of care. Participants will be recruited in participating centers, where they are planning on starting (neo-) adjuvant ACT-based chemotherapy and/or trastuzumab for stage I-III breast cancer.

Timeline

Start

2023-10-19

Primary completion

2025-04-19

Completion

2025-04-19

Publications

• Greco A, Quagliariello V, Rizzo G, Tedeschi A, Schirinzi S, Turco A, Galiazzo M, Acquaro M, De Amicis M, Klersy C, Ghio S, Perrone L, Paccone A, Uccello G, Canale ML, Oliva S, Guerra F, De Luca L, Maurea N, Scelsi L. SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial. Cardiooncology. 2025 Sep 1;11(1):79. doi: 10.1186/s40959-025-00368-9.

Drugs

Indications